カテゴリー： QYResearch, 世界

脾腫治療法の世界市場：規模・現状・予測2019-2025

【英語タイトル】Global Splenomegaly Therapeutics Market Size, Status and Forecast 2019-2025

QYResearchが出版した調査資料（DATA909X18996）・商品コード：DATA909X18996
・発行会社（調査会社）：QYResearch
・発行日：2019年11月25日（※2024年版があります。お問い合わせください）
・ページ数：96
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥577,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥865,800見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,800 ⇒換算￥1,154,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※当調査レポートでは、脾腫治療法の世界市場について調査・分析し、脾腫治療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（薬物療法、予防接種、その他）、用途別（正常（脾腫ではない）、中程度の脾腫、重度の脾腫）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。


・レポートの概要
・世界の脾腫治療法市場動向
・主要企業別マーケットシェア
・脾腫治療法の種類別市場規模2014-2019
（薬物療法、予防接種、その他）
・脾腫治療法の用途別市場規模2014-2019
（正常（脾腫ではない）、中程度の脾腫、重度の脾腫）
・脾腫治療法の北米市場：主要企業・種類別/用途別市場規模
・脾腫治療法のヨーロッパ市場：主要企業・種類別/用途別市場規模
・脾腫治療法の中国市場：主要企業・種類別/用途別市場規模
・脾腫治療法の日本国内市場：主要企業・種類別/用途別市場規模
・脾腫治療法の東南アジア市場：主要企業・種類別/用途別市場規模
・脾腫治療法のインド市場：主要企業・種類別/用途別市場規模
・脾腫治療法の中南米市場：主要企業・種類別/用途別市場規模
・主要企業のプロフィール
（GlaxoSmithKline plc、Incyte Corporation、Merck & Co., Inc.、Novartis AG、Sanofi）
・脾腫治療法の市場規模予測2019-2025
（種類別、用途別、地域別市場予測）
・アナリストの観点・結論
...
【レポートの概要】

Splenomegaly is an enlargement of the spleen.The spleen usually lies in the left upper quadrant (LUQ) of the human abdomen. Splenomegaly is one of the four cardinal signs of hypersplenism which include: some reduction in number of circulating blood cells affecting granulocytes, erythrocytes or platelets in any combination; a compensatory proliferative response in the bone marrow; and the potential for correction of these abnormalities by splenectomy. The increasing demand for targeted therapy is one of the critical reasons that will drive splenomegaly therapeutics market growth. Targeted therapy is a novel approach used to treat malignancies without harming the peripheral healthy cells of the body. This is done by singling out and targeting the specific receptors present in cancer cells. The therapeutic benefits of this innovative approach are encouraging many institutes to increase their R&D investments in targeted therapy. The adoption of molecular-targeted therapies for the treatment of splenomegaly to reduce the spleen size will continue to improve.
In 2018, the global Splenomegaly Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Splenomegaly Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Splenomegaly Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
GlaxoSmithKline plc
Incyte Corporation
Merck & Co., Inc.
Novartis AG
Sanofi
…

Market segment by Type, the product can be split into
Drug Therapy
Vaccination
Others

Market segment by Application, split into
Normal (Not Splenomegaly)
Moderate Splenomegaly
Severe Splenomegaly

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Splenomegaly Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Splenomegaly Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Splenomegaly Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Splenomegaly Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Drug Therapy
1.4.3 Vaccination
1.4.4 Others
1.5 Market by Application
1.5.1 Global Splenomegaly Therapeutics Market Share by Application (2019-2025)
1.5.2 Normal (Not Splenomegaly)
1.5.3 Moderate Splenomegaly
1.5.4 Severe Splenomegaly
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Splenomegaly Therapeutics Market Size
2.2 Splenomegaly Therapeutics Growth Trends by Regions
2.2.1 Splenomegaly Therapeutics Market Size by Regions (2019-2025)
2.2.2 Splenomegaly Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Splenomegaly Therapeutics Market Size by by Players
3.1.1 Global Splenomegaly Therapeutics Revenue by by Players (2014-2019)
3.1.2 Global Splenomegaly Therapeutics Revenue Market Share by by Players (2014-2019)
3.1.3 Global Splenomegaly Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Splenomegaly Therapeutics Key Players Head office and Area Served
3.3 Key Players Splenomegaly Therapeutics Product/Solution/Service
3.4 Date of Enter into Splenomegaly Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Splenomegaly Therapeutics Market Size by Type (2014-2019)
4.2 Global Splenomegaly Therapeutics Market Size by Application (2014-2019)

5 North America
5.1 North America Splenomegaly Therapeutics Market Size (2014-2019)
5.2 Splenomegaly Therapeutics Key Players in North America
5.3 North America Splenomegaly Therapeutics Market Size by Type
5.4 North America Splenomegaly Therapeutics Market Size by Application

6 Europe
6.1 Europe Splenomegaly Therapeutics Market Size (2014-2019)
6.2 Splenomegaly Therapeutics Key Players in Europe
6.3 Europe Splenomegaly Therapeutics Market Size by Type
6.4 Europe Splenomegaly Therapeutics Market Size by Application

7 China
7.1 China Splenomegaly Therapeutics Market Size (2014-2019)
7.2 Splenomegaly Therapeutics Key Players in China
7.3 China Splenomegaly Therapeutics Market Size by Type
7.4 China Splenomegaly Therapeutics Market Size by Application

8 Japan
8.1 Japan Splenomegaly Therapeutics Market Size (2014-2019)
8.2 Splenomegaly Therapeutics Key Players in Japan
8.3 Japan Splenomegaly Therapeutics Market Size by Type
8.4 Japan Splenomegaly Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Splenomegaly Therapeutics Market Size (2014-2019)
9.2 Splenomegaly Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Splenomegaly Therapeutics Market Size by Type
9.4 Southeast Asia Splenomegaly Therapeutics Market Size by Application

10 India
10.1 India Splenomegaly Therapeutics Market Size (2014-2019)
10.2 Splenomegaly Therapeutics Key Players in India
10.3 India Splenomegaly Therapeutics Market Size by Type
10.4 India Splenomegaly Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Splenomegaly Therapeutics Market Size (2014-2019)
11.2 Splenomegaly Therapeutics Key Players in Central & South America
11.3 Central & South America Splenomegaly Therapeutics Market Size by Type
11.4 Central & South America Splenomegaly Therapeutics Market Size by Application

12 International Players Profiles
12.1 GlaxoSmithKline plc
12.1.1 GlaxoSmithKline plc Company Details
12.1.2 Company Description and Business Overview
12.1.3 Splenomegaly Therapeutics Introduction
12.1.4 GlaxoSmithKline plc Revenue in Splenomegaly Therapeutics Business (2014-2019))
12.1.5 GlaxoSmithKline plc Recent Development
12.2 Incyte Corporation
12.2.1 Incyte Corporation Company Details
12.2.2 Company Description and Business Overview
12.2.3 Splenomegaly Therapeutics Introduction
12.2.4 Incyte Corporation Revenue in Splenomegaly Therapeutics Business (2014-2019)
12.2.5 Incyte Corporation Recent Development
12.3 Merck & Co., Inc.
12.3.1 Merck & Co., Inc. Company Details
12.3.2 Company Description and Business Overview
12.3.3 Splenomegaly Therapeutics Introduction
12.3.4 Merck & Co., Inc. Revenue in Splenomegaly Therapeutics Business (2014-2019)
12.3.5 Merck & Co., Inc. Recent Development
12.4 Novartis AG
12.4.1 Novartis AG Company Details
12.4.2 Company Description and Business Overview
12.4.3 Splenomegaly Therapeutics Introduction
12.4.4 Novartis AG Revenue in Splenomegaly Therapeutics Business (2014-2019)
12.4.5 Novartis AG Recent Development
12.5 Sanofi
12.5.1 Sanofi Company Details
12.5.2 Company Description and Business Overview
12.5.3 Splenomegaly Therapeutics Introduction
12.5.4 Sanofi Revenue in Splenomegaly Therapeutics Business (2014-2019)
12.5.5 Sanofi Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Splenomegaly Therapeutics Key Market Segments
Table Key Players Splenomegaly Therapeutics Covered
Table Global Splenomegaly Therapeutics Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Drug Therapy Figures
Table Key Players of Drug Therapy
Figuer Vaccination Figures
Table Key Players of Vaccination
Figuer Others Figures
Table Key Players of Others
Table Global Splenomegaly Therapeutics Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Splenomegaly Therapeutics Market Share by Application in 2018 & 2025
Figure Normal (Not Splenomegaly) Case Studies
Figure Moderate Splenomegaly Case Studies
Figure Severe Splenomegaly Case Studies
Figure Splenomegaly Therapeutics Report Years Considered
Figure Global Splenomegaly Therapeutics Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Splenomegaly Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Splenomegaly Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Splenomegaly Therapeutics Market Share by Regions 2014-2019
Figure Global Splenomegaly Therapeutics Market Share by Regions 2014-2019
Figure Global Splenomegaly Therapeutics Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Splenomegaly Therapeutics Revenue by by Players (2014-2019) (Million US$)
Table Global Splenomegaly Therapeutics Market Share by by Players (2014-2019)
Figure Global Splenomegaly Therapeutics Market Share by by Players in 2018
Table Global Splenomegaly Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Splenomegaly Therapeutics Product/Solution/Service
Table Date of Enter into Splenomegaly Therapeutics Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Splenomegaly Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Global Splenomegaly Therapeutics Market Size Share by Type (2014-2019)
Figure Global Splenomegaly Therapeutics Market Size Market Share by Type (2014-2019)
Table Global Splenomegaly Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Global Splenomegaly Therapeutics Market Size Share by Application (2014-2019)
Figure Global Splenomegaly Therapeutics Market Size Market Share by Application (2014-2019)
Figure Global Splenomegaly Therapeutics Revenue Market Share by Application in 2018
Figure North America Splenomegaly Therapeutics Market Size 2014-2019 (Million US$)
Table North America Key Players Splenomegaly Therapeutics Revenue (2018-2019) (Million US$)
Table North America Key Players Splenomegaly Therapeutics Market Share (2018-2019)
Table North America Splenomegaly Therapeutics Market Size by Type 2014-2019 (Million US$)
Table North America Splenomegaly Therapeutics Market Share by Type 2014-2019
Table North America Splenomegaly Therapeutics Market Size by Application 2014-2019 (Million US$)
Table North America Splenomegaly Therapeutics Market Share by Application 2014-2019
Figure Europe Splenomegaly Therapeutics Market Size 2014-2019 (Million US$)
Table Europe Key Players Splenomegaly Therapeutics Revenue (2018-2019) (Million US$)
Table Europe Key Players Splenomegaly Therapeutics Market Share (2018-2019)
Table Europe Splenomegaly Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Europe Splenomegaly Therapeutics Market Share by Type 2014-2019
Table Europe Splenomegaly Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Europe Splenomegaly Therapeutics Market Share by Application 2014-2019
Figure China Splenomegaly Therapeutics Market Size 2014-2019 (Million US$)
Table China Key Players Splenomegaly Therapeutics Revenue (2018-2019) (Million US$)
Table China Key Players Splenomegaly Therapeutics Market Share (2018-2019)
Table China Splenomegaly Therapeutics Market Size by Type 2014-2019 (Million US$)
Table China Splenomegaly Therapeutics Market Share by Type 2014-2019
Table China Splenomegaly Therapeutics Market Size by Application 2014-2019 (Million US$)
Table China Splenomegaly Therapeutics Market Share by Application 2014-2019
Figure Japan Splenomegaly Therapeutics Market Size 2014-2019 (Million US$)
Table Japan Key Players Splenomegaly Therapeutics Revenue (2018-2019) (Million US$)
Table Japan Key Players Splenomegaly Therapeutics Market Share (2018-2019)
Table Japan Splenomegaly Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Japan Splenomegaly Therapeutics Market Share by Type 2014-2019
Table Japan Splenomegaly Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Japan Splenomegaly Therapeutics Market Share by Application 2014-2019
Figure Southeast Asia Splenomegaly Therapeutics Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Splenomegaly Therapeutics Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Splenomegaly Therapeutics Market Share (2018-2019)
Table Southeast Asia Splenomegaly Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Southeast Asia Splenomegaly Therapeutics Market Share by Type 2014-2019
Table Southeast Asia Splenomegaly Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Southeast Asia Splenomegaly Therapeutics Market Share by Application 2014-2019
Figure India Splenomegaly Therapeutics Market Size 2014-2019 (Million US$)
Table India Key Players Splenomegaly Therapeutics Revenue (2018-2019) (Million US$)
Table India Key Players Splenomegaly Therapeutics Market Share (2018-2019)
Table India Splenomegaly Therapeutics Market Size by Type 2014-2019 (Million US$)
Table India Splenomegaly Therapeutics Market Share by Type 2014-2019
Table India Splenomegaly Therapeutics Market Size by Application 2014-2019 (Million US$)
Table India Splenomegaly Therapeutics Market Share by Application 2014-2019
Figure Central & South America Splenomegaly Therapeutics Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Splenomegaly Therapeutics Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Splenomegaly Therapeutics Market Share (2018-2019)
Table Central & South America Splenomegaly Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Central & South America Splenomegaly Therapeutics Market Share by Type 2014-2019
Table Central & South America Splenomegaly Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Central & South America Splenomegaly Therapeutics Market Share by Application 2014-2019
Table GlaxoSmithKline plc Company Details
Table GlaxoSmithKline plc Revenue in Splenomegaly Therapeutics Business 2014-2019 (Million US$)
Figure GlaxoSmithKline plc Revenue Growth Rate in Splenomegaly Therapeutics Business (2014-2019)
Table GlaxoSmithKline plc Recent Development
Table Incyte Corporation Company Details
Table Incyte Corporation Revenue in Splenomegaly Therapeutics Business 2014-2019 (Million US$)
Figure Incyte Corporation Revenue Growth Rate in Splenomegaly Therapeutics Business (2014-2019)
Table Incyte Corporation Recent Development
Table Merck & Co., Inc. Company Details
Table Merck & Co., Inc. Revenue in Splenomegaly Therapeutics Business 2014-2019 (Million US$)
Figure Merck & Co., Inc. Revenue Growth Rate in Splenomegaly Therapeutics Business (2014-2019)
Table Merck & Co., Inc. Recent Development
Table Novartis AG Company Details
Table Novartis AG Revenue in Splenomegaly Therapeutics Business 2014-2019 (Million US$)
Figure Novartis AG Revenue Growth Rate in Splenomegaly Therapeutics Business (2014-2019)
Table Novartis AG Recent Development
Table Sanofi Company Details
Table Sanofi Revenue in Splenomegaly Therapeutics Business 2014-2019 (Million US$)
Figure Sanofi Revenue Growth Rate in Splenomegaly Therapeutics Business (2014-2019)
Table Sanofi Recent Development
Table Global Splenomegaly Therapeutics Market Size by Regions (Million US$) 2019-2025
Figure Global Splenomegaly Therapeutics Market Size Share by Regions (2019-2025)
Figure Global Splenomegaly Therapeutics Market Size Share by Regions in 2025
Figure North America Splenomegaly Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Europe Splenomegaly Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure China Splenomegaly Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Japan Splenomegaly Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Splenomegaly Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure India Splenomegaly Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Splenomegaly Therapeutics Market Size Forecast (2019-2025)(Million USD)
Table Global Splenomegaly Therapeutics Market Size by Product (2019-2025) (Million US$)
Figure Global Splenomegaly Therapeutics Market Size by Product (2019-2025)
Figure Global Splenomegaly Therapeutics Market Size by Product in 2025
Table Global Splenomegaly Therapeutics Market Size by Application (2019-2025) (Million US$)
Figure Global Splenomegaly Therapeutics Market Size by Application (2019-2025)
Figure Global Splenomegaly Therapeutics Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

GlaxoSmithKline plc、Incyte Corporation、Merck & Co., Inc.、Novartis AG、Sanofi

★調査レポート[脾腫治療法の世界市場：規模・現状・予測2019-2025] (コード：DATA909X18996)販売に関する免責事項を必ずご確認ください。
★調査レポート[脾腫治療法の世界市場：規模・現状・予測2019-2025]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • アテローム性動脈硬化症治療薬の世界市場：規模・現状・予測2019-2025
    DATA909X18181 / QYResearch / 2019年11月25日 / ※当調査レポートでは、アテローム性動脈硬化症治療薬の世界市場について調査・分析し、アテローム性動脈硬化症治療薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（小分子、生物製剤）、用途別（病院、クリニック、研究所、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界のアテローム性動脈硬化症治療薬市場動向 ・主要企業別マーケットシェア ・アテローム性動脈硬化症治療薬の種類別市場規模2014-2019 （小分子、生物製剤） ・アテローム性動脈硬化症治療薬の用途別市場規模2014-2019 （病院、クリニック、研究所、その他） ・アテローム性動脈硬化症治療薬の北米市場：主要企業・種類別/用途別市場規模 ・アテローム性動脈硬化症治療薬のヨーロッパ市場：主要企業・種類別/用途別市場規模...Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as the first line of treatment for decreasing LDL levels in the body, it exhibits secondary effects, such as hepatic enzyme elevation or muscular pain in some patients. Moreover, statins do not decrease the risk of cardiovascular diseases completely and is not recommended for patients having diabetes. This has encouraged researchers to focus on...
  • 胆嚢癌療法の世界市場：規模・現状・予測2019-2025
    DATA909X18497 / QYResearch / 2019年11月25日 / ※当調査レポートでは、胆嚢癌療法の世界市場について調査・分析し、胆嚢癌療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（併用療法、単剤療法）、用途別（病院、医学研究所、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の胆嚢癌療法市場動向 ・主要企業別マーケットシェア ・胆嚢癌療法の種類別市場規模2014-2019 （併用療法、単剤療法） ・胆嚢癌療法の用途別市場規模2014-2019 （病院、医学研究所、クリニック、その他） ・胆嚢癌療法の北米市場：主要企業・種類別/用途別市場規模 ・胆嚢癌療法のヨーロッパ市場：主要企業・種類別/用途別市場規模...Rising incidence of cholelithiasis, chronic inflammation of the gallbladder, and gallbladder polyps are contributing to the prevalence of gallbladder cancer. This has resulted in a rise in demand for therapeutics for treating the condition.Surgery is considered the primary treatment approach for gallbladder cancer, which involves the complete removal of the organ. However, the second line of treatment involves the use of radiation therapy along with chemotherapeutics. The rising availability of financial assistance programs is further helping patients in availing these high-cost treatments. With the increasing occurrence of these risk factors, the need for gallbladder cancer therapeutics will subsequently increase over...

    • ◆H&Iグローバルリサーチのお客様（例）◆